Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + pemetrexed + cisplatin or carboplatin
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination regimen is a first-line chemotherapy treatment being investigated for patients with advanced epidermal growth factor receptor (EGFR) wild-type non-squamous non-small cell lung cancer (NSCLC). The regimen consists of apatinib, an oral small-molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor-2 (VEGFR-2) to inhibit tumor angiogenesis, combined with a platinum-based doublet chemotherapy. The chemotherapy component is either pemetrexed plus cisplatin (referred to as AP in the trial context) or pemetrexed plus carboplatin (referred to as AC). This therapeutic approach aims to leverage the synergistic effects of anti-angiogenic therapy and standard cytotoxic chemotherapy to improve clinical outcomes in advanced lung cancer patients. The study is primarily led by West China Hospital.
- Brand names
- AiTanAlimtaPlatinolParaplatin
- Other names
- Apatinib + APApatinib + ACApatinib + Pemetrexed + CisplatinApatinib + Pemetrexed + Carboplatinapatinib mesylate
02
Targets
DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)GART (GAR transformylase)DNARET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on apatinib + pemetrexed + cisplatin or carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + pemetrexed + cisplatin or carboplatin.